Brexit means that access to research networks and funding could be impaired, and the mobility of scientists, researchers and company staff limited. Moreover, the relocation of the European Medicines Agency will bring its own staffing and recruitment problems, and the possibility of regulatory divergences between the UK and the EU threatens to delay new drug approvals and clinical trials.
While the life science sector is well accustomed to adapting to rapidly changing circumstances, the upheavals and uncertainties brought by...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?